Cardiac Dimensions is a developer and developer of cardiovascular and cerebrovascular disease therapies aimed at addressing heart failure and related cardiovascular diseases. The company’s lead product – the Carillon Mitral Contour System® – uses a minimally invasive approach designed to restore natural mitral valve function without damaging the mitral valve leaflets. Cardiac Dimensions raised $35 million in Series D funding. The round was co-led by Horizon 3 Healthcare and an undisclosed strategic investor, with participation from Arboretum Ventures, Hostplus, EQT Life Sciences, Lumira Ventures and MH Carnegie & Co.
This article is transferred from: https://www.itjuzi.com/investevent/13761148
This site is only for collection, and the copyright belongs to the original author.